Introduction to Pharmacokinetics and Pharmacodynamics

Size: px
Start display at page:

Download "Introduction to Pharmacokinetics and Pharmacodynamics"

Transcription

1 Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001

2 Vocabulary Clearance Renal elimination: filtration aminoglycosides are primarily filtered AMG clearance best approximates GFR beta-lactams (penicillins and cephalosporins) secretion penicillin has highest secretion rates > 80% other beta-lactams are secreted to varying degrees (0-60%)

3 Vocabulary Clearance Hepatic or Hepatobiliary: antibiotics not routinely monitored dosage adjustments in hepatic insufficiency are not clearly defined macrolides (erythromycin, clarithromycin, azithromycin) clindamycin metronidazole nafcillin, oxacillin, ceftriaxone

4 Vocabulary Volume of distribution - depends upon: hydrophilicity and lipophilicity of the drug the size of the patient aminoglycosides & β-lactams ~ L/kg hydrophilic drugs, distributes into extracellular water spaces, NOT into fat tissue dehydrated or cachectic patients have a smaller Vd larger for fluid overloaded patients, observed frequently in ICUs for AMG dosing weight is IBW or if obese an adjusted BW

5 Vocabulary Half-life - time required for a drug concentration to decrease by one-half AMG with normal renal function ~ 2-3h Penicillins with normal renal function ~ 1h Cephalosporins with normal renal function ~ 2h Vancomycin with normal renal function ~ 4-6h

6 Vocabulary Distribution Phase - time from the end of the infusion for drug concentrations to equilibrate between the tissue and blood Most critical in evaluating peak drug concentrations AMG - complete ~ minutes after end of infusion Elimination Phase determination of elimination rate constant

7 Pharmacokinetics body s effect on the drug Overview half-life, Vd, ke, Cmax, Cmin, protein binding Pharmacodynamics the drugs effect on the biological system (organism) Synergy relationship of drug concentrations to killing activity Post antibiotic effect Methodologies and interpretations

8 MICs and MBCs MIC (minimum inhibitory concentration) lowest drug concentration that inhibits bacterial growth MBC (minimum bactericidal concentration) lowest drug concentration that kills bacteria MBCs are not routinely tested in clinical labs Drug A Drug B Drug C Drug D Drug E

9 Bacteriostatic vs. Bactericidal Static Cidal Time (h) B a c t e r i a l C o u n t l 1 0 ( C F U / m l

10 Pharmacodynamics Two classifications related to drug concentration & killing activity Concentration Independent Concentration Dependent Parameters Time above MIC Peak to MIC ratio AUC to MIC ratio

11 Concentration Independent Killing Maximal killing activity achieved at about 4-5 times the MIC Pharmacodynamic parameter most important is T > MIC Cell wall active agents penicillins, cephalosporins, glycopeptides Log 10 CFU/ml 9 Ticarcillin Time (h) Control 1/4 MIC 1 MIC 4 MIC 16 MIC Craig, Ebert. Scand J Infect Dis 1991.

12 Concentration Independent Killing To improve the pharmacodynamic profile of betalactam drugs and/or vancomycin, shortening the dosing interval is significantly more beneficial than increasing the dose Cefepime half-life ~ 2 hrs, dosed q8 or 12 hours, MIC = 2-4 mcg/ml time 1 gram 2 gram 0h 70 mcg/ml 140 mcg/ml 2h h h h h h

13 Schematic of T > MIC Concentration µg/ml Drug conc. MIC 8 g/ml (7.8 12)*100 = 65% Time (h)

14 AUC:MIC Ratio Often important parameter for quinolones For gram-negative infections if ratio > 125 there is a good correlation to a good clinical outcome For gram-positive infections the ratio has yet to be established proposed value is > 30

15 Concentration Dependent Killing Killing activity increases with increasing drug concentrations, maximal killing is achieved at about times the MIC Pharmacodynamic parameter most important is Peak:MIC Intracellular active agents aminoglycosides, fluoroquinolones Log 10 CFU/ml Tobramycin Time (h) Control 1/4 MIC 1 MIC 4 MIC 16 MIC 64 MIC Craig, Ebert. Scand J Infect Dis 1991.

16 Post Antibiotic Effect Refers to the time period after removal of an antibiotic (or subinhibitory concentrations) during which there is no bacterial growth AMG conc MIC Time (h) Bacterial Colony Count AMG Conc Bacterial Growth

17 Post Antibiotic Effect Type of antimicrobial agent Against gram-negative bacilli Penicillins, aztreonam, trimethoprim, & sulfonamides possess minimal to no PAE Cephalosporins?? short to intermediate duration (0.5-2h); inconsistent results Aminoglycosides, imipenem, fluoroquinolones intermediate to long (2-3h or more)

18 Post Antibiotic Effect Mechanism(s) of the PAE Unknown, however, theory is that for each agent & organism the exact mechanisms vary and are multiple Time required for new PBPs to be synthesized Time required to synthesize new ribosomes Time required for dissociation of the antimicrobial/ribosome complexes

19 PAE & Dosing Regimen 9 Concentration (mcg/ml) PAE Divided dose MIC Time (h)

20 Drawing Blood for Determination of Serum Levels Concentration (mcg/ml) False C max, and false elimination rate (slope is falsely steep) True C max and elimination rate Time (h)

21 Antibiotics Dosed Pharmacokinetically Therapeutic and toxic concentration range are very close to each other Aminoglycosides (AMG) (always) gentamicin, tobramycin, amikacin peak concentration dependent upon dosing method and type of infection trough concentration less than 1 mcg/ml Vancomycin (sometimes) peak concentration not clinically relevant for most infections trough concentration 5-10 mcg/ml

22 Aminoglycoside toxicities Nephrotoxicity and ototoxicity are associated with AUC or elevated trough concentrations NOT peak concentrations Nephrotoxicity and ototoxicity risk factors renal dysfunction age duration of therapy liver dysfunction concomitant use of other toxic drugs

23 AMG Divided Daily Dosing Gentamicin/Tobramycin 1-2 mg/kg q?h Amikacin 7.5 mg/kg q?h dosing interval increases as renal function decreases to maintain a trough concentration < 1 mcg/ml (gent & tob) < 4 mcg/ml (amik) q12h, q24h, q36h, q48h, q72h Targeted Peak Serum Concentrations Disease State Gent/Tob µg/ml Amik µg/ml Cystitis All other infections Pneumonia

24 AMG High Dose Once Daily Gentamicin/Tobramycin 4-7 mg/kg q24h Amikacin 15 mg/kg q24h Trough concentrations should always be nondetectable Targeted Peak Serum Concentrations Disease State Gent/Tob µg/ml Amik µg/ml Cystitis All other infections Pneumonia

25 Loading Dose Equation Loading Dose = Vd * desired C max If a patient is 60 kg then Vd = 0.3 L/kg * 60 kg = 18 L Disease state is osteomyelitis and gentamicin is the drug requested C max is 6-8 mcg/ml (mg/l) for DDD, Loading dose = 18 L* 8 mg/l = 144 mg dosing interval is renal function dependent or if using HDOD then the target peak is and LD = 18 L * 14 mg/l = 252 mg dosing interval is q24h

26 Synergy The effect of the drug combination is greater than the sum of the effects of the individual agents Mechanism: increased uptake of one drug caused by the second drug (AMG + beta-lactam) sequential blockade (TMP/SMX) beta-lactamase inactivation (amoxicillin/clavulanate)

27 Synergy Traditional testing for synergy: Fractional Inhibitory Concentration (FIC) FIC < 0.5 = synergism; FIC > 4 = antagonism Killing Curves > 2 log increase in killing over the most active single agent Synergy testing is not routinely performed in clinical laboratories. Exception: screening for likelihood of synergy of gentamicin or streptomycin with ampicillin or vancomycin against entercocci

28 Synergy Rationale for combination therapy: enhance killing of organism (synergy) minimize the development of resistance Combinations routinely used in clinical practice for the synergistic effect: against gram-negative bacilli aminoglycosides + beta-lactams against enterococci gentamicin or streptomycin + ampicillin gentamicin or streptomycin + vancomycin against staphylococci nafcillin or vancomycin + gentamicin + rifampin

29 Example Test Question Pharmacodynamics relate killing activity of antibiotics to pharmacokinetic parameters. Which of the following parameters is most associated with the killing activity of quinolones? A. peak:mic ratio B. T > MIC C. AUC:MIC ratio D. A and C

30 In Conclusion... Pharmacokinetic parameters half-life, clearance, volume of distribution, C max, C min Pharmacodynamic parameters T > MIC, Peak:MIC ratio, AUC:MIC ratio Concentration Dependent vs. Independent killing Post-antibiotic effect Synergy Most important with concentration dependent drugs Useful in treating both gram-positive and gram-negative infections

Antimicrobial Pharmacodynamics

Antimicrobial Pharmacodynamics Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they

More information

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008 Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin

More information

Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient

Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient Rania El-Lababidi, Pharm.D., BCPS (AQ-ID), AAHIVP Manager, Pharmacy Education and Training Cleveland Clinic Abu Dhabi

More information

General Infectious Disease Concepts/Resources

General Infectious Disease Concepts/Resources General Infectious Disease Concepts/Resources Learning Objectives: 1. Distinguish between foundational infectious disease concepts including gram positive and negative bacteria, bacteriostatic and bactericidal

More information

CHSPSC, LLC Antimicrobial Stewardship Education Series

CHSPSC, LLC Antimicrobial Stewardship Education Series CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy

More information

Chapter 51. Clinical Use of Antimicrobial Agents

Chapter 51. Clinical Use of Antimicrobial Agents Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a

More information

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,

More information

Jerome J Schentag, Pharm D

Jerome J Schentag, Pharm D Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases

More information

DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*

DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* 44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine

More information

Introduction to Antimicrobial Therapy

Introduction to Antimicrobial Therapy Introduction to Antimicrobial Therapy Christine Kubin Classification of Antimicrobials Antimicrobials are drugs that destroy microbes, prevent their multiplication or growth, or prevent their pathogenic

More information

Effective 9/25/2018. Contact for previous versions.

Effective 9/25/2018. Contact for previous versions. Pharmacokinetic and Pharmacodynamic Dose Optimization of Antibiotics (β-lactams, aminoglycosides, and ciprofloxacin) for the Treatment of Gram-Negative Infections Adult Inpatient/Emergency Department Clinical

More information

Principles of Antimicrobial Therapy

Principles of Antimicrobial Therapy Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality

More information

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug

More information

Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy

Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy

More information

Antimicrobial therapy in critical care

Antimicrobial therapy in critical care Antimicrobial therapy in critical care KARLEE JOHNSTON LEAD PHARMACIST DIVISION OF CRITICAL CARE CANBERRA HOSPITAL AND HEALTH SERVICE Outline 1. Let s talk about sepsis 2. PK/PD considerations 3. Selecting

More information

Introduction to Antimicrobial Therapy

Introduction to Antimicrobial Therapy Introduction to Antimicrobial Therapy Christine Kubin, Pharm.D., BCPS Clinical Pharmacist, Infectious Diseases Case #2 68 y.o. female with HTN, anxiety with chest pain symptoms 7/27/05: Cath - 3 vessel

More information

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers

More information

MICU Antibiotics and Associated Drug Interactions

MICU Antibiotics and Associated Drug Interactions MICU Antibiotics and Associated Drug Interactions Resistant Bacteria MICU patient are at risk for resistant organisms: Recent hospitalizations From a skilled nursing facility Immunocompromised patients

More information

CF WELL Pharmacology: Microbiology & Antibiotics

CF WELL Pharmacology: Microbiology & Antibiotics CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure

More information

Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals

Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals Tom Dilworth, PharmD Aurora Health Care thomas.dilworth@aurora.org Objectives Describe the pharmacokinetics and pharmacodynamics

More information

Introduction to Antimicrobials. Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail.

Introduction to Antimicrobials. Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail. Introduction to Antimicrobials Rachel J. Gordon, MD, MPH Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail. Major Learning Objectives: 1) Learn the different

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

Principles of Antimicrobial therapy

Principles of Antimicrobial therapy Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or

More information

Appropriate Antimicrobial Therapy for Treatment of

Appropriate Antimicrobial Therapy for Treatment of Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul

More information

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES THE AMINOGLYCOSIDES:

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES THE AMINOGLYCOSIDES: CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug

More information

Bacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota

Bacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated

More information

Objectives. Introduction to Antimicrobial Therapy. What are Antimicrobials??? Classification of Antimicrobials. Case Presentation #1

Objectives. Introduction to Antimicrobial Therapy. What are Antimicrobials??? Classification of Antimicrobials. Case Presentation #1 Introduction to Antimicrobial Therapy Objectives Review the classification of antimicrobials Define pharmacokinetic and pharmacodynamic principles and their relationship to effective antimicrobial therapy

More information

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

Approach to pediatric Antibiotics

Approach to pediatric Antibiotics Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus

More information

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1 Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination

More information

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram

More information

Introduction to Antimicrobial Therapy

Introduction to Antimicrobial Therapy Case #1 Introduction to Antimicrobial Therapy Christine Kubin, Pharm.D., BCPS Clinical Pharmacist, Infectious Diseases L.G. is a 78 yo woman admitted for cardiac cath. 3-vessel disease was identified and

More information

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2. AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony

More information

Curricular Components for Infectious Diseases EPA

Curricular Components for Infectious Diseases EPA Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize

More information

UPDATES ON ANTIBIOTIC THERAPY. Jennifer L. Davis, DVM, PhD, DACVIM (LA), DACVCP VA-MD College of Veterinary Medicine VA Tech, Blacksburg, VA

UPDATES ON ANTIBIOTIC THERAPY. Jennifer L. Davis, DVM, PhD, DACVIM (LA), DACVCP VA-MD College of Veterinary Medicine VA Tech, Blacksburg, VA UPDATES ON ANTIBIOTIC THERAPY Jennifer L. Davis, DVM, PhD, DACVIM (LA), DACVCP VA-MD College of Veterinary Medicine VA Tech, Blacksburg, VA ANTIBIOTICS Fluoroquinolones The fluoroquinolone class of antibiotics

More information

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016

Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016 Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that

More information

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What

More information

Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017

Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017 Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,

More information

Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill

Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill Arthur RH van Zanten, MD PhD Internist-intensivist Department of Intensive care Gelderse Vallei Hospital, Ede The Netherlands

More information

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:

More information

Tel: Fax:

Tel: Fax: CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.

More information

Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections

Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg

More information

Pharmacology Week 6 ANTIMICROBIAL AGENTS

Pharmacology Week 6 ANTIMICROBIAL AGENTS Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe

More information

Antimicrobials & Resistance

Antimicrobials & Resistance Antimicrobials & Resistance History 1908, Paul Ehrlich - Arsenic compound Arsphenamine 1929, Alexander Fleming - Discovery of Penicillin 1935, Gerhard Domag - Discovery of the red dye Prontosil (sulfonamide)

More information

Protein Synthesis Inhibitors

Protein Synthesis Inhibitors Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors

More information

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.

These recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017. Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing

More information

Cell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017

Cell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017 Cell Wall Inhibitors Assistant Professor Naza M. Ali Lec 3 7 Nov 2017 Cell wall The cell wall is a rigid outer layer, it completely surrounds the cytoplasmic membrane, maintaining the shape of the cell

More information

ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS

ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS Contents 1. How to I calculate a gentamicin dose?... 2 2. How do I prescribe gentamicin on the cardex?... 2 3. Can I give

More information

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010 Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter

More information

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:

More information

January 2014 Vol. 34 No. 1

January 2014 Vol. 34 No. 1 January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital

More information

Antimicrobial Susceptibility Testing: The Basics

Antimicrobial Susceptibility Testing: The Basics Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories

More information

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Routine internal quality control as recommended by EUCAST Version 3.1, valid from Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut

Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY

More information

Patients. Excludes paediatrics, neonates.

Patients. Excludes paediatrics, neonates. Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All

More information

Animal models and PK/PD. Examples with selected antibiotics

Animal models and PK/PD. Examples with selected antibiotics Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh

More information

* gender factor (male=1, female=0.85)

* gender factor (male=1, female=0.85) Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12

More information

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for

More information

Antimicrobial Susceptibility Patterns

Antimicrobial Susceptibility Patterns Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department

More information

1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 TRADE NAME OF THE MEDICINAL PRODUCT Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2ml contains 20mg of Gentamicin as Gentamicin Sulfate Excipient

More information

Why we perform susceptibility testing

Why we perform susceptibility testing 22 nd June 2015 Why we perform susceptibility testing Robin A Howe Antimicrobial use in Primary Care Why do we perform AST? Clinical Clinical Prediction Prediction of of Efficacy Efficacy Why do we perform

More information

number Done by Corrected by Doctor Dr Hamed Al-Zoubi

number Done by Corrected by Doctor Dr Hamed Al-Zoubi number 8 Done by Corrected by Doctor Dr Hamed Al-Zoubi 25 10/10/2017 Antibacterial therapy 2 د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy Figure 2/ Antibiotics target Inhibition of microbial

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

Management of Native Valve

Management of Native Valve Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis

More information

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه

More information

Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections

Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections ...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment

More information

Rational use of antibiotics

Rational use of antibiotics Rational use of antibiotics Uga Dumpis MD, PhD,, DTM Stradins University Hospital Riga, Latvia ugadumpis@stradini.lv BALTICCARE CONFERENCE, PSKOV, 16-18.03, 18.03, 2006 Why to use antibiotics? Prophylaxis

More information

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site

More information

Antimicrobials Update

Antimicrobials Update Antimicrobials Update Rosie Amini, PharmD. BCPS Antimicrobial Stewardship Program Coordinator Swedish Medical Center Disclosures: Dr. Amini has no significant financial interest in any of the products

More information

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck! Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which

More information

Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections

Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections ...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

OPAT discharge navigator and laboratory monitoring Select OPAT button for ALL patients that discharge on intravenous antimicrobials

OPAT discharge navigator and laboratory monitoring Select OPAT button for ALL patients that discharge on intravenous antimicrobials Clinical Monitoring of Outpatient Parenteral Antimicrobial Therapy (OPAT) and Selected Oral Antimicrobial Agents Adult Inpatient/Ambulatory Clinical Practice Guideline Appendix A. Coordinating an OPAT

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

EUCAST recommended strains for internal quality control

EUCAST recommended strains for internal quality control EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC

More information

Other Beta - lactam Antibiotics

Other Beta - lactam Antibiotics Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

Update on Therapeutic Drug Monitoring - Aminoglycosides. Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015

Update on Therapeutic Drug Monitoring - Aminoglycosides. Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015 Update on Therapeutic Drug Monitoring - Aminoglycosides Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust What are common

More information

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

Systemic Antimicrobial Prophylaxis Issues

Systemic Antimicrobial Prophylaxis Issues Systemic Antimicrobial Prophylaxis Issues Pierre Moine Department of Anesthesiology University of Colorado Denver 3 rd International Conference on Surgery and Anesthesia OMICs Group Conference The Surgical

More information

Considerations in antimicrobial prescribing Perspective: drug resistance

Considerations in antimicrobial prescribing Perspective: drug resistance Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,

More information

Antibiotics 1. Lecture 8

Antibiotics 1. Lecture 8 Antibiotics 1 Lecture 8 Overview of antibiotics What am I treating? Viral, bacterial, fungal, mycobacterial, etc. Who am I treating? Host factors: age, genetic factors, co-morbidities (renal and liver

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

Cell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification

Cell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification Cell Wall Weakeners Antimicrobials: Drugs that Weaken the Cell Wall Beta Lactams Penicillins Cephalosporins Carbapenems Aztreonam Vancomycin Teicoplanin Bacterial Cell Wall Bacterial cytoplasm is hypertonic

More information

Antimicrobial susceptibility

Antimicrobial susceptibility Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

BUGS and DRUGS Part 1 March 6, 2013 Marieke Kruidering- Hall

BUGS and DRUGS Part 1 March 6, 2013 Marieke Kruidering- Hall BUGS and DRUGS Part 1 March 6, 2013 Marieke Kruidering- Hall BIOGRAPHY: Marieke Kruidering- Hall is Associate Professor in the Department of Cellular & Molecular Pharmacology. She was born in the Netherlands.

More information

Antibiotics & Resistance

Antibiotics & Resistance What are antibiotics? Antibiotics & esistance Antibiotics are molecules that stop bacteria from growing or kill them Antibiotics, agents against life - either natural or synthetic chemicals - designed

More information

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information

Central Nervous System Infections

Central Nervous System Infections Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY

More information

GENERAL NOTES: 2016 site of infection type of organism location of the patient

GENERAL NOTES: 2016 site of infection type of organism location of the patient GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered

More information

ENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN

ENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST

More information